Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-033, an Anti-LAG-3 Monoclonal Antibody, Alone and in Combination With an Anti-PD-1 in Patients With Advanced Solid Tumors

NCT03250832 is registered in ClinicalTrials.gov with Tesaro, Inc. as lead sponsor.

NCT NCT03250832
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03250832 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-033, an Anti-LAG-3 Monoclonal Antibody, Alone and in Combination With an Anti-PD-1 in Patients With Advanced Solid Tumors
Lead sponsor
Tesaro, Inc.
Phase
Phase 1
Overall status
Completed
Start date
August 8, 2017
Completion date
February 13, 2023
Enrollment
111 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

neoplasms